EGFR and non-small cell lung carcinoma: Apart from the initial findings on t(15;19) translocations involving aberrant activation of Notch3 in NSCLCs, the activity of this receptor has also been found required during treatment refractoriness evolution in EGFR mutant NSCLC [101].